Clinical characteristics of patients with t-AML
| UPN . | Sex . | Age, y . | Prior disease or cancer . | Alk . | XRT . | Topo . | Other chemo . | Latency (years)* . | % BM blast . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|
| 180365 | F | 54 | AML | Y | Y | Y | Y | ∼7.8 | 83 | 47,XX,+8[18]/46,XX[2] |
| 180866 | M | 66 | Multiple myeloma | Y | Y | Y | Y | 3.2 | Not done | 47,XY,+i(8)(q10)[3] / 47,XY,+8[17] |
| 189941 | F | 42 | Ovarian/breast | Y | Y | Y | Y | 5.6 | 76 | 45, XX,add(3)(q27),del(3)(q12),-4,del(5)(q12q33),-7,+add(18)(p11.1),+mar,+mar1[cp19]/46,XX[1] |
| 205133 | F | 59 | Breast | Y | Y | N | Y | 7.0 | 36 | 46,XX[30] |
| 266608 | M | 80 | Renal cell carcinoma | N | N | N | Y | 6.4 | 33 | 46,XY[20] |
| 317821 | F | 42 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 1.1 | 80 | 36-46,XX,+der(1;7)(p10;q10),add(1)(q42),del(7)(q11.2),der(?)t(?;7)(?::7q11.2->7qter)[cp10] |
| 377512 | F | 74 | Non-Hodgkin lymphoma | N | N | Y | Y | 2.4 | 31 | 38-51,XX,add(1)(p13),del(1)(p36.1),del(1)(q12),der(2)t(2;15)(q37;q11.2), add(3)(q29)-5,del(7)(q31),add(8)(p23),r(8)(?p22q24),add(13)(p11.2), iso(13)(q10),add(19)(q13.4),add(20)(p?13),iso(21)(q10)[cp20] |
| 458613 | M | 28 | Hodgkin lymphoma | N | Y | N | N | 1.5 | 90 | 46,XY,inv(16)(p13.1q22)[18] / 46,XY[2] |
| 476081 | F | 68 | Breast | Y | Y | Y | Y | 1.6 | 66 | 46,XX[20] |
| 476204 | F | 51 | Breast | Y | Y | Y | Y | 6.8 | 87 | 46,XX[20] |
| 482711 | F | 57 | Breast | Y | Y | Y | Y | 11.8 | 44 | 44-45,XX,der(4)t(4;?)(q22;?)[3],-5[10],add(6)(q13)[6, del(7)(q22)[10], del(12)(p11.2)[4],-17[6],+mar[4],+2mar[3],add(19)(q13)[4] / 46,XX[10] |
| 501254 | F | 67 | Breast | Y | Y | Y | Y | 1.4 | 95 | 46,XX,t(11;19)(q23;p13)[16] / 47,idem,+8[4] |
| 514901 | F | 63 | Breast | N | Y | N | Y | 1.15 | 95 | 46,XX,t(6;11)(q27;q23)[20]/46,XX[7] |
| 530447 | M | 43 | Hodgkin lymphoma | Y | Y | Y | Y | 12.8 | 40 | 44,XY,-3,-5,-7,add(9)(p21),add(17)(q25),+mar1[8] / 45,sl,+mar2[11]/48,sdl1,+21,+22,+r[1] |
| 548417 | F | 77 | Breast | Y | N | Y | Y | 7.3 | 95 | 46,XX[20] |
| 557772 | M | 60 | Multiple myeloma | Y | N | Y | Y | 3.3 | 47 | 49,XY,-5,+8,+11,-17,-17,+21,+22,+2mar[19] / 50,idem,+mar[1] |
| 572162 | F | 59 | Breast | Y | Y | Y | Y | 4.75 | 79 | 46,XX,t(3;12)(p13;p13)[5]/46,XX[15] |
| 644242 | F | 56 | Breast | Y | Y | Y | Y | 4.0 | 62 | 46,XX,t(8;21)(q22;q22)[19] |
| 658208 | M | 50 | Multiple sclerosis | N | N | Y | N | 2.8 | 94 | 45,X,-Y,t(8;21)(q22;q22)[19] |
| 706395 | F | 45 | Lung | Y | Y | Y | Y | 1.9 | 90 | 46,XX,t(9;11)(p21;q23)[16] / 46,idem,der(1)(t(1;?)(p13;?)[2] / 46,XX[2] |
| 751407 | M | 74 | Rheumatoid arthritis | N | N | N | Y | 1.5 | 61 | 85,XXY,-Y,-2,-5,-7,-16,-17,-18 [10]/46,XY[10] |
| 779828 | M | 79 | Prostate | N | Y | N | N | 2.1 | 76 | 46,XY[20] |
| 811184 | M | 26 | Non-Hodgkin lymphoma | Y | N | Y | N | NK | 56 | 42∼46, XY, der(11)t(11;15)(p11.2;q11.1), t(11;19)(q23;p13), del(13)(q22), −15, add(22)(q11.1)[cp7]/46,XY[6] |
| 856024 | M | 26 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 1.1 | 90 | 46,XY,der(12)t(1;12)(q25;p13),add(12)(q24.2)[18] / 46,XY[2] |
| 860923 | F | 71 | Non-Hodgkin lymphoma | Y | Y | N | Y | 6.9 | 71 | 92,XXXX[6] / 46,XX[14] |
| 864484 | M | 39 | Testicular | N | Y | N | Y | 1.1 | 92 | 42-48,XY,-2,inv(7)(p15q11.2),-11,-13,del(13)(q12q21),-17,der(19)t(?;19)(?;p13.1),+mar1,+mar2,+mar3,+mar4,+mar5[cp20] |
| 925964 | F | 58 | Uterine | N | N | Y | Y | 2.2 | 38 | 46,XX,inv(11)(p15q22∼23)[19] / 46,XX[1] |
| 942008 | M | 69 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 13.3 | 67 | 45,der(X)t(X;16)(p22.1;p13.2),add(X)(q26),Y,t(3;9)(p13;q34),del(5)(q13q31),inv(6)(p21.1q25),der(7)(7pter->q21∼q22;?),der(16)t(X;16)(p22.1;p13.2)[2] / 92,der(X)t(X;16)(p22.1;p13.2),add(X)(q26)x2,Y,t(3;9)(p13;q34)x2,del(5)(q13q31)x2,inv(6)(p21.1q25)x2,der(7)(7pter->q21∼q22;?)x2,der(16)t(X;16)(p22.1;p13.2)x2[1] / 46,XY[27] |
| 982895 | F | 47 | Breast | N | Y | N | Y | ∼3 | 93 | 46,XX,t(9;11)(p22;q23)[7]/47, idem, +8[13] |
| 983545 | F | 61 | Breast | Y | Y | N | Y | 1.4 | 41 | 49,XX,ins(6)(?q13?),+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)(p22;q23),del(13)(q12q14)[7] / 49,XX,idem,+del(13)(q12q14)[7] / 46,XX[5] |
| UPN . | Sex . | Age, y . | Prior disease or cancer . | Alk . | XRT . | Topo . | Other chemo . | Latency (years)* . | % BM blast . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|
| 180365 | F | 54 | AML | Y | Y | Y | Y | ∼7.8 | 83 | 47,XX,+8[18]/46,XX[2] |
| 180866 | M | 66 | Multiple myeloma | Y | Y | Y | Y | 3.2 | Not done | 47,XY,+i(8)(q10)[3] / 47,XY,+8[17] |
| 189941 | F | 42 | Ovarian/breast | Y | Y | Y | Y | 5.6 | 76 | 45, XX,add(3)(q27),del(3)(q12),-4,del(5)(q12q33),-7,+add(18)(p11.1),+mar,+mar1[cp19]/46,XX[1] |
| 205133 | F | 59 | Breast | Y | Y | N | Y | 7.0 | 36 | 46,XX[30] |
| 266608 | M | 80 | Renal cell carcinoma | N | N | N | Y | 6.4 | 33 | 46,XY[20] |
| 317821 | F | 42 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 1.1 | 80 | 36-46,XX,+der(1;7)(p10;q10),add(1)(q42),del(7)(q11.2),der(?)t(?;7)(?::7q11.2->7qter)[cp10] |
| 377512 | F | 74 | Non-Hodgkin lymphoma | N | N | Y | Y | 2.4 | 31 | 38-51,XX,add(1)(p13),del(1)(p36.1),del(1)(q12),der(2)t(2;15)(q37;q11.2), add(3)(q29)-5,del(7)(q31),add(8)(p23),r(8)(?p22q24),add(13)(p11.2), iso(13)(q10),add(19)(q13.4),add(20)(p?13),iso(21)(q10)[cp20] |
| 458613 | M | 28 | Hodgkin lymphoma | N | Y | N | N | 1.5 | 90 | 46,XY,inv(16)(p13.1q22)[18] / 46,XY[2] |
| 476081 | F | 68 | Breast | Y | Y | Y | Y | 1.6 | 66 | 46,XX[20] |
| 476204 | F | 51 | Breast | Y | Y | Y | Y | 6.8 | 87 | 46,XX[20] |
| 482711 | F | 57 | Breast | Y | Y | Y | Y | 11.8 | 44 | 44-45,XX,der(4)t(4;?)(q22;?)[3],-5[10],add(6)(q13)[6, del(7)(q22)[10], del(12)(p11.2)[4],-17[6],+mar[4],+2mar[3],add(19)(q13)[4] / 46,XX[10] |
| 501254 | F | 67 | Breast | Y | Y | Y | Y | 1.4 | 95 | 46,XX,t(11;19)(q23;p13)[16] / 47,idem,+8[4] |
| 514901 | F | 63 | Breast | N | Y | N | Y | 1.15 | 95 | 46,XX,t(6;11)(q27;q23)[20]/46,XX[7] |
| 530447 | M | 43 | Hodgkin lymphoma | Y | Y | Y | Y | 12.8 | 40 | 44,XY,-3,-5,-7,add(9)(p21),add(17)(q25),+mar1[8] / 45,sl,+mar2[11]/48,sdl1,+21,+22,+r[1] |
| 548417 | F | 77 | Breast | Y | N | Y | Y | 7.3 | 95 | 46,XX[20] |
| 557772 | M | 60 | Multiple myeloma | Y | N | Y | Y | 3.3 | 47 | 49,XY,-5,+8,+11,-17,-17,+21,+22,+2mar[19] / 50,idem,+mar[1] |
| 572162 | F | 59 | Breast | Y | Y | Y | Y | 4.75 | 79 | 46,XX,t(3;12)(p13;p13)[5]/46,XX[15] |
| 644242 | F | 56 | Breast | Y | Y | Y | Y | 4.0 | 62 | 46,XX,t(8;21)(q22;q22)[19] |
| 658208 | M | 50 | Multiple sclerosis | N | N | Y | N | 2.8 | 94 | 45,X,-Y,t(8;21)(q22;q22)[19] |
| 706395 | F | 45 | Lung | Y | Y | Y | Y | 1.9 | 90 | 46,XX,t(9;11)(p21;q23)[16] / 46,idem,der(1)(t(1;?)(p13;?)[2] / 46,XX[2] |
| 751407 | M | 74 | Rheumatoid arthritis | N | N | N | Y | 1.5 | 61 | 85,XXY,-Y,-2,-5,-7,-16,-17,-18 [10]/46,XY[10] |
| 779828 | M | 79 | Prostate | N | Y | N | N | 2.1 | 76 | 46,XY[20] |
| 811184 | M | 26 | Non-Hodgkin lymphoma | Y | N | Y | N | NK | 56 | 42∼46, XY, der(11)t(11;15)(p11.2;q11.1), t(11;19)(q23;p13), del(13)(q22), −15, add(22)(q11.1)[cp7]/46,XY[6] |
| 856024 | M | 26 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 1.1 | 90 | 46,XY,der(12)t(1;12)(q25;p13),add(12)(q24.2)[18] / 46,XY[2] |
| 860923 | F | 71 | Non-Hodgkin lymphoma | Y | Y | N | Y | 6.9 | 71 | 92,XXXX[6] / 46,XX[14] |
| 864484 | M | 39 | Testicular | N | Y | N | Y | 1.1 | 92 | 42-48,XY,-2,inv(7)(p15q11.2),-11,-13,del(13)(q12q21),-17,der(19)t(?;19)(?;p13.1),+mar1,+mar2,+mar3,+mar4,+mar5[cp20] |
| 925964 | F | 58 | Uterine | N | N | Y | Y | 2.2 | 38 | 46,XX,inv(11)(p15q22∼23)[19] / 46,XX[1] |
| 942008 | M | 69 | Non-Hodgkin lymphoma | Y | Y | Y | Y | 13.3 | 67 | 45,der(X)t(X;16)(p22.1;p13.2),add(X)(q26),Y,t(3;9)(p13;q34),del(5)(q13q31),inv(6)(p21.1q25),der(7)(7pter->q21∼q22;?),der(16)t(X;16)(p22.1;p13.2)[2] / 92,der(X)t(X;16)(p22.1;p13.2),add(X)(q26)x2,Y,t(3;9)(p13;q34)x2,del(5)(q13q31)x2,inv(6)(p21.1q25)x2,der(7)(7pter->q21∼q22;?)x2,der(16)t(X;16)(p22.1;p13.2)x2[1] / 46,XY[27] |
| 982895 | F | 47 | Breast | N | Y | N | Y | ∼3 | 93 | 46,XX,t(9;11)(p22;q23)[7]/47, idem, +8[13] |
| 983545 | F | 61 | Breast | Y | Y | N | Y | 1.4 | 41 | 49,XX,ins(6)(?q13?),+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)(p22;q23),del(13)(q12q14)[7] / 49,XX,idem,+del(13)(q12q14)[7] / 46,XX[5] |
Alk, alkylator chemotherapy; chemo, chemotherapy; N, no; Topo, topoisomerase chemotherapy; XRT, radiation therapy; Y, yes.
Latency, time (years) from treatment of original cancer.